

Medicated Tampon (Duaferm™)

PHARMACEUTICAL PRODUCT OPPORTUNITY

*Entirely New and
Different Way to
Treat Heavy
Menstrual Bleeding*



We have developed
and patented a
potential breakthrough
product for a highly
prevalent condition



Fits into typical use of
sanitary products –
most convenient
option



Creates new, very
large market
segment with no
competition



Hundreds of
millions in potential
sales for both Rx
and OTC

OUR INNOVATION AND PROPRIETARY POSITION



Local delivery of antifibrinolytics was never applied to heavy menstrual bleeding.



Three patent applications developed with a top intellectual property firm.



Supported by scientific data: potentially most efficacious and safest therapy.



A patent is currently being pursued in the US.



“Novel, proprietary” medicated feminine sanitary products (menstrual tampons or menstrual pads).



A 10-year protection is already secured in Germany.



The patent applications are developed and owned by the ARSTAT’s principal - Arkady Rubin, PhD., a researcher with 25 years of pharma industry experience. Dr. Rubin is expertly knowledgeable in the treatment of dysfunctional uterine bleeding; he has analyzed extensive clinical databases and co-authored related publications.

SCIENTIFIC DETAILS

RIGHT DRUG

Proven ability to control menstrual bleeding.
Strong local effects in various clinical settings.

DELIVERED ON TARGET


Uterine fibrinolytic activity elevated during menstrual periods.
Especially in women with heavy menstrual bleeding.

FOR FAST AND STRONG ACTION

Rapid and significant bleeding reduction.
Exceeding clinical targets for heavy menstrual bleeding.

WITH VERY LOW, SAFE DOSES

Hardly detectable circulating drug levels.
Doses much lower than those administered orally.



CLINICAL ADVANTAGES



Unlike with oral antifibrinolytics (**Lysteda®**), menstrual bleeding could be reduced to normal levels in most of women.



Unlike with hormonal contraceptives, Duafem does not stop or alter menstrual cycles; women may conceive if pregnancy is desired.



Duafem is safer and less costly vs. endometrial ablation and other surgical procedures.

DEVELOPMENT DETAILS



US precedent: another medicated tampon was approved by the FDA with no clinical studies.



If efficacy data required, testing starts with Phase 2b; earliest VC exit in 2.5-3 years.



Clinical data **proves** the **concept** and greatly increases the odds of Success.




Proven feasibility of a medicated menstrual tampon.

HUGE MARKET



22 MILLION

22 million US women suffer from heavy menstrual bleeding. **7 million** of them are clinically diagnosed with menorrhagia.




20% of women worldwide report heavy bleeding (WHO).



70 MILLION

Most of normally menstruating women (**~70 million** in the US) want to avoid occasional days of heavy bleeding.

UNDERDIAGNOSED AND UNDERTREATED



Lack of disease Awareness.



Poor safety & efficacy of existing therapies.

GREAT COMMERCIAL OPPORTUNITY



Could capture
≈\$350M/year for a
prescription (Rx)
formulation (20-25%
of the US market).



Over-the-counter
(OTC) sales could be up
to \$650M/year (4-5%
of the \$14B feminine
hygiene global market).

VALUE PROPOSITION

**The intellectual property
is offered to
pharmaceutical
companies and venture
capital firms.**

*Although we prefer a sale of
the IP, we would also consider
out-licensing or other flexible
arrangements, including joint
development.*



CONTACT

Arkady Rubin, PhD

✉ arubin@arstatinc.com



347-385-0878

